Tonix Pharmaceuticals Holding Corp.

509 Madison Avenue, Suite 1608

New York, New York 10022

September 9, 2019

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

	Re:	Tonix Pharmaceuticals Holding Corp.
		Registration Statement on Form S-1 (File No. 333-233445)

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, Tonix Pharmaceuticals Holding Corp. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at 4:30 p.m., Eastern Standard Time, on September 11, 2019, or as soon as practicable thereafter.

Please call Alan Wovsaniker of Lowenstein Sandler LLP at (973) 597-2564 to confirm the effectiveness of the Registration Statement or with any questions.

[Signature page follows.]

U.S. Securities and Exchange Commission

September 9, 2019

Page 2

	Very truly yours,

	TONIX PHARMACEUTICALS HOLDINGS CORP.


	By:	/s/ Bradley Saenger
	Name:	Bradley Saenger
	Title:	Chief Financial Officer

- 2 -